Fungototal

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fungototal

Property Description
Active ingredient Fluconazole
Form Capsule, tablet, oral suspension, intravenous solution
Pharmacological class Systemic Antifungal Agent (Triazole-class)
Common use Treating fungal infections (mycoses)
Origin Synthetic compound

What Type of Medicine is Fungototal? (Identity and Classification)

Fungototal is a prescription medicine whose active component is Fluconazole, classifying it as a Systemic Antifungal Agent. This drug belongs to the triazole-class of antifungals and is a synthetic compound specifically designed to combat internal or widespread fungal infections. Fluconazole is characterized by a broad range of activity against common pathogenic fungi and is used in treating systemic infections.

As a synthetic substance, Fluconazole's chemical structure is a difluorophenyl-triazole alcohol derivative. Its classification as a systemic agent signifies that, upon administration, it is absorbed into the bloodstream to reach and treat infections throughout the body, providing a comprehensive internal defense against fungal pathogens (mycoses).


Composition and Available Forms of Fungototal (Structure and Presentation)

The composition of Fungototal is based on a single active ingredient, Fluconazole, which is presented in multiple pharmaceutical preparations to suit various clinical needs. The medicine is commonly supplied in forms for oral administration, including capsules, tablets, or a powder for oral suspension. This oral liquid form is a distinctive feature, often utilized for the pediatric patient group or individuals who have difficulty swallowing solid medications.

For clinical settings or for patients unable to take oral medication, Fungototal is also manufactured as a sterile solution for intravenous injection. This active substance is rapidly and extensively absorbed after oral administration, allowing the oral forms to work effectively for systemic action.


What is the General Purpose of Fungototal? (High-Level Function)

The general purpose of Fungototal is to eliminate the fungi responsible for infections requiring systemic treatment. Its function is based on selectively targeting the fungal pathogen through a mechanism known as ergosterol synthesis inhibition, which exerts a fungistatic action.

This targeted action involves blocking a specific fungal enzyme essential for building the fungal cell membrane—the protective outer layer of the fungus. By interfering with the cell membrane's structural integrity, the drug stops the fungus from growing and replicating, directly addressing the underlying cause of the fungal infection.

Regulatory References

  1. Fluconazole - StatPearls - NCBI Bookshelf

What side effects are possible with Fungototal?

Possible side effects and safety information

The safety profile of Fungototal (Fluconazole) is established in official regulatory documents, classifying potential effects by the affected physiological system and documented frequency. Adverse reactions are grouped using standard System-Organ Class (SOC) categories and frequency definitions used by global health authorities.


Frequency-Classified Adverse Reactions

The most frequently reported adverse event is Headache, classified as very common. Reactions classified as Common primarily involve the Gastrointestinal system, including Nausea, Vomiting, Diarrhea, and Abdominal pain. Common effects also include elevations in laboratory markers of liver function, such as increased Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST).


Serious Adverse Reactions and Safety Constraints

Regulatory labeling specifies the potential for rare, serious events involving critical organ systems. These include serious hepatic toxicity, such as Hepatic failure, and severe cardiac rhythm abnormalities, including QT prolongation and Torsade de pointes, which are typically reported in seriously ill patients with underlying risk factors.

Less frequent but severe skin reactions like Toxic Epidermal Necrolysis and Stevens-Johnson syndrome are also documented.

Safety Constraints note that elimination of the active substance is significantly impacted by reduced renal function. Caution is specified for patients with pre-existing cardiac conditions or when co-administered with specific drugs known to affect the heart’s electrical system, due to the increased potential for cardiotoxicity.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of antifungal medications such as Fungototal should be taken seriously, as excessive use can lead to heightened risk of serious adverse effects involving the central nervous system and cardiovascular system. While official documentation for "Fungototal" may be limited, the overdose profile of related triazole antifungals indicates key symptoms to monitor.

Documented manifestations of acute overdose in this class can include a combination of hallucinations and paranoia (extreme fear/suspiciousness). High exposure may also be associated with serious complications affecting the heart rhythm, specifically the risk of QTc prolongation, which can lead to life-threatening conditions like Torsades de Pointes.

Urgent medical attention is required immediately if an overdose is suspected or if any of the following severe symptoms occur: a change in consciousness, seizures, an abnormal or fast heart rhythm, difficulty breathing, or signs of severe liver injury such as yellowing of the skin or eyes (jaundice), dark urine, or pale stools.

Due to the potential for systemic toxicity and the risk of serious neurological and cardiac events, any accidental or intentional ingestion exceeding the prescribed dose should prompt an immediate call to emergency services or a national poison control center for expert guidance and management.

Therapeutic Uses of Fungototal

Main Uses and Therapeutic Benefits of Fungototal

Fungototal (Fluconazole) is used for symptomatic management of fungal infections, generally applied in addressing the fungal pathogens responsible for various infections and mitigating the resulting symptom burden. It is commonly used across conditions where supportive relief from infectious manifestations is needed. The medication is relevant in the therapeutic domains of both treatment and prophylaxis.

The medicine is used for managing conditions that present with systemic or localized discomfort, including Candidemia, Cryptococcal meningitis, and various forms of mucosal candidiasis such as oral, esophageal, and recurrent vaginal infections. Fungototal generally helps manage highly distressing symptoms, contributing to easing discomfort and supporting the maintenance of functional stability, particularly in patients with recurrent or widespread disease.

“The use is relevant for easing symptomatic discomfort that supports patients during episodes of heightened discomfort.”

The medication may also be part of symptomatic management as a prophylactic measure to assist with managing the risk of developing opportunistic fungal infections in immunocompromised patients.


Contextual Note: Relevant for Mucosal Inflammation and Systemic Discomfort

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Fungototal (Fluconazole) eligibility is defined by official regulatory criteria, specifying populations who may use the medicine, those who require conditional use, and groups for whom the drug is strictly prohibited.

Absolute Contraindications

Use is strictly contraindicated in patients with a known hypersensitivity to Fluconazole or related azole antifungals. It is also prohibited for patients concurrently taking certain medicinal products that prolong the QT interval and are metabolized by the CYP3A4 enzyme (e.g., cisapride, pimozide, quinidine). High-dose and prolonged use during pregnancy is contraindicated outside of life-threatening situations.

Conditional Use and Restrictions

The medicine is generally allowed for adults, older adults, and pediatric patients. However, use requires caution in patients with pre-existing hepatic impairment and those with risk factors for heart rhythm problems. Patients with impaired renal function require a formal dose adjustment for multiple-dose regimens. Specific dosing frequency adjustments are mandated for newborn infants. Regulatory agencies state that safety and efficacy for genital candidiasis are not established in the pediatric population.

Pregnancy and Lactation Status

Women of childbearing potential must use effective contraceptive measures during treatment and for approximately one week after the final dose. Use during lactation is not recommended with repeated or high doses, though it may be maintained after a single standard dose.

What should I know about interactions with other medicines?

Fungototal (fluconazole) is a strong inhibitor of the cytochrome P450 enzymes CYP2C19 and a moderate inhibitor of CYP2C9 and CYP3A4. This enzyme inhibition causes an increase in the plasma concentration and prolonged exposure of numerous co-administered medicinal products metabolized by these pathways.

Contraindicated Combinations

Co-administration is contraindicated with certain medicines that are both substrates of CYP3A4 and are known to prolong the QT interval. This includes specific drugs such as Pimozide, Quinidine, and Halofantrine, due to the potential for severe cardiotoxicity, including Torsades de Pointes. Co-administration with Erythromycin is also contraindicated due to the risk of cardiotoxicity.

Required Monitoring and Adjustment

Use with numerous other medicines metabolized by the inhibited CYP enzymes requires close monitoring and potential dosage reduction of the co-administered drug. This includes anticoagulants like Warfarin, where prothrombin time must be closely checked; specific statins (e.g., Atorvastatin, Simvastatin), which increase the risk of rhabdomyolysis; and immunosuppressants such as Cyclosporine and Tacrolimus.

Inducers of CYP enzymes, such as Rifampicin, can lead to reduced Fungototal plasma concentrations and may necessitate appropriate adjustments. The inhibiting effect of Fungototal can persist for approximately four to five days after treatment discontinuation due to its long half-life.

Mechanism of Action

u1f52c Targeted Inhibition of Fungal Cell Structure Enzymes

Fungototal operates by engaging the Lanosterol 14-alpha-demethylase (CYP51) enzyme, a key molecular target exclusive to the fungal pathogen. This highly selective inhibitory action blocks a crucial step in the cell's ergosterol biosynthesis pathway, which is necessary for constructing the protective outer membrane. This core domain initiates a mechanistic cascade leading to structural compromise of the pathogen.


u1f4a5 Cell Membrane Collapse and Proliferation Arrest

The enzymatic blockade causes the depletion of functional ergosterol while simultaneously creating toxic, abnormal sterols that accumulate in the cell membrane. This structural compromise results in increased permeability and functional failure of the fungal cell's outer barrier, leading to a fungistatic consequence. This mechanism arrests the fungal population's ability to grow and replicate.


u1f6e1 Limitations Due to Fungal Counter-Mechanisms

The efficacy of the drug’s inhibitory action is constrained by the pathogen’s adaptive biological responses. The mechanism can be overridden in situations involving innate resistance or acquired resistance, where fungi either overexpress the target enzyme (CYP51) or increase the activity of efflux pumps to actively remove the drug from the cell. These constraints define scenarios where the mechanism’s inhibitory effect on fungal growth is reduced or circumvented.

Dosage and Administration Information

How to Use Fungototal

Fungototal (fluconazole) is used according to specific administration guidelines for the systemic treatment of fungal infections. The medicine is available for two primary administration routes: oral (using capsules, tablets, or liquid suspension) or intravenous (IV) infusion.


Dosing Regimens and Schedules

Treatment typically begins with a loading dose—often double the daily maintenance amount—administered on the first day to quickly achieve necessary drug levels. This is followed by a maintenance dose taken once daily for the remainder of the course. For some conditions, such as uncomplicated vaginal candidiasis, a single oral dose is prescribed. The duration of use varies significantly, ranging from a short single day up to several months for chronic suppressive therapy.


Administration Requirements

Usage Constraint Labeled Instruction
Timing in Relation to Food Oral forms may be taken with or without food
IV Infusion Rate The intravenous solution must be administered slowly, at a rate not exceeding 10 mL/minute
Oral Suspension Preparation Must be shaken well before each use and measured using a marked device
Route Equivalence The daily dose remains unchanged when switching a patient between the oral and intravenous routes

Population-Specific Adjustments

Specific adjustments are made for patients with reduced renal function. If creatinine clearance is less than or equal to 50 mL/min (and the patient is not on dialysis), the dose is generally reduced by 50% after the initial loading dose. Patients undergoing regular hemodialysis must receive the full recommended dose after each dialysis session.

Recent Clinical Evidence

Research evidence / Overview of studies

The following summary describes the outcomes that were examined in clinical research. This information is not medical advice.


Summary of Major Clinical Findings

Research has evaluated the use of the compound in individuals with [Condition Name, e.g., Onychomycosis]. Multiple studies have consistently reported an association with a [quantified finding, e.g., 70% mycological cure rate] in individuals receiving the compound. Studies have explored whether the compound is associated with changes in the frequency and severity of [Symptom 1] and [Symptom 2].

  • Trial X (Phase III, Double-Blind): This trial included [Number] participants with [Condition]. Investigators examined whether compound use was associated with a change in the primary endpoint, which was defined as [Endpoint definition, e.g., complete clinical and mycological cure]. The time course and duration of the observed effect were explored.
  • Trial Y (Meta-analysis): This study analyzed data from [Number] smaller-scale trials, focusing on consistency of findings across different populations. The pooled analysis explored a potential association between the compound's use and endpoints relevant to [Symptom, e.g., fungal recurrence].

Studies on Combination Approaches

Research has specifically focused on populations diagnosed with [Condition Name] who did not respond fully to other interventions.

Investigators have explored a potential link between compound use and endpoints relevant to [Complication, e.g., secondary bacterial infection]. Studies have conducted comparisons between the combination approach (compound + [Standard Treatment]) and a standard intervention alone. One trial investigated a potential association between compound use and changes in [Biomarker, e.g., inflammatory markers] over a 12-month period.

Studies excluded individuals with [Co-morbidity X, e.g., moderate-to-severe hepatic impairment] from participation, limiting the available evidence regarding the compound's profile in this group. The reviewed trials provided limited evidence regarding the long-term outcomes and potential interactions with [Specific Drug Class, e.g., Azole antifungals].

Frequently Asked Questions (FAQ)

Common questions about Fungototal (FAQ)


Q: Why does Fungototal need to be taken for a long period in some cases?

A: Official product information states that the duration of treatment with Fungototal varies significantly based on the specific type and severity of the fungal infection. Treatment for systemic or chronic infections may last several weeks to months. The treatment duration is determined by the healthcare provider, and it is intended to continue until clinical or laboratory results suggest the active fungal infection has been successfully addressed.

Q: Are there any specific foods or drinks I need to avoid while on Fungototal?

A: Regulatory information indicates that oral forms of Fungototal can be taken with or without food, as food intake does not significantly affect how the medicine is absorbed. The official drug label does not list any specific foods or drinks that must be avoided during treatment.

Q: What happens if I miss a dose of Fungototal? Do I take two doses next time?

A: According to official drug guidance, if a dose is missed, it can typically be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. In that instance, the missed dose is usually skipped, and the regular schedule is resumed. Official guidance cautions against taking a double dose to compensate for a missed one.

Q: Are there any natural remedies that interact negatively with Fungototal?

A: Fungototal is known to inhibit (block) certain Cytochrome P450 enzymes in the body. Because many other compounds, including herbal products, are broken down by these same enzymes, this could potentially increase the concentration of those co-administered compounds. For this reason, individuals are encouraged to discuss all supplements or herbal remedies they may be taking with a healthcare provider.

Q: Has Fungototal been studied in pregnant or breastfeeding women?

A: Regulatory guidance states that high-dose and prolonged use of Fungototal during pregnancy is generally considered contraindicated (prohibited) outside of life-threatening situations, due to potential risks identified in animal studies and rare human reports. The drug passes into breast milk, and therefore, use during lactation is typically not recommended with repeated or high doses.

Q: Why is Fungototal sometimes used for nail infections and other times for skin issues?

A: Fungototal is an approved systemic antifungal agent indicated for treating a wide variety of fungal infections throughout the body. This includes infections of the skin, such as athlete's foot (tinea pedis) and ringworm (tinea corporis), as well as deeper fungal infections like onychomycosis (nail infections), when systemic treatment is considered necessary.

Q: Are there any serious, but rare, side effects of Fungototal I should know about?

A: Official labeling specifies potential for rare, severe events. These include serious liver toxicity (like hepatic failure), severe allergic-type skin reactions (such as Stevens-Johnson Syndrome), and heart rhythm problems (QT prolongation). Patients are advised to contact their healthcare provider right away if they notice signs associated with these serious side effects, such as persistent vomiting, jaundice (yellowing of the skin or eyes), or a severe rash.

Q: What should I do if my symptoms seem to be getting worse on Fungototal?

A: If symptoms do not improve, or seem to worsen after starting treatment with Fungototal, it may indicate that the fungal infection is not responding as expected, possibly due to resistance. If this occurs, the prescriber should be consulted, as further evaluation may be necessary to consider whether alternative therapies are required.

Q: Is Fungototal effective against all types of fungal infections?

A: Fungototal is a broad-spectrum antifungal, but its effectiveness is not guaranteed against all types of fungal infections. Regulatory information notes that the prevalence of resistance is increasing for certain species of Candida and other fungi, which may limit the drug’s effectiveness in those specific cases.

Q: Can Fungototal be crushed or chewed if someone has trouble swallowing pills?

A: The regulatory documents for the capsules and tablets typically advise swallowing them whole. However, Fungototal is also manufactured as an oral liquid suspension, which is often an option for patients, particularly children, who have difficulty swallowing solid medication.

Q: Does Fungototal need to be stored in the refrigerator or at room temperature?

A: Storage instructions vary depending on the formulation. The oral capsules and tablets must be stored at controlled room temperature, typically between 20 C and 25 C. The oral liquid suspension must be stored between 5 C and 30 C after it is mixed, and it is important that this form is not frozen.

Q: Does taking Fungototal affect my ability to drive or operate machinery?

A: Official product information advises patients to take caution when driving vehicles or operating machinery. This is because adverse effects such as dizziness or seizures have occasionally been reported, which could potentially impair the ability to safely perform these tasks.

Q: Can Fungototal be used as a preventative measure for recurrent infections?

A: Yes, regulatory approvals indicate that Fungototal can be used for certain preventative purposes. This includes long-term suppressive therapy to prevent relapse of cryptococcal disease in specific patient groups, and preventing certain deep-seated fungal infections in high-risk patients.

Q: Are there any known drug-drug interactions that are dangerous with Fungototal?

A: Yes, Fungototal is strictly contraindicated (prohibited) with certain drugs that affect heart rhythm and are metabolized by the CYP3A4 enzyme, such as Pimozide, Quinidine, and Halofantrine. Co-administration with the antibiotic Erythromycin is also contraindicated due to the documented risk of severe cardiotoxicity.

Q: Is it possible to develop a resistance to Fungototal over time?

A: Yes, regulatory information acknowledges that the efficacy of the drug can be limited by acquired resistance. This occurs when the fungal pathogen adapts by either over-producing the enzyme Fungototal targets or by increasing its ability to actively pump the drug out of the cell.

Q: How quickly can I expect Fungototal to start working after the first dose?

A: In some cases, a high loading dose is given on the first day to help achieve effective drug levels in the bloodstream rapidly. However, the exact time it takes for a patient to feel noticeable relief from their symptoms is variable and is highly dependent on the type and location of the infection being treated.

Q: Is it normal to feel a bit nauseous when starting Fungototal?

A: Nausea is classified in regulatory documents as a Common side effect, meaning it is one of the more frequently reported adverse events in clinical trials. While it may not be experienced by every patient, it is a known and common reaction to the medicine.

Q: Does Fungototal affect birth control pills?

A: Official labeling notes that studies have shown Fungototal can cause a small increase in the plasma concentration of components found in oral contraceptives. While the clinical significance of this change is generally considered low, prescribers are made aware of this potential interaction.

Q: Is it true that Fungototal can make your skin more sensitive to the sun?

A: While not explicitly listed as a common side effect, some regulatory information advises caution regarding sun exposure. This is due to the potential for severe skin reactions, which are known to be associated with the medication, and the possibility of increased photosensitivity. The potential for severe skin reactions is associated with the medication, which means that caution regarding sun exposure is generally advised.

Q: How long after finishing the course of Fungototal can I expect to feel fully better?

A: The active substance in Fungototal has a long half-life, meaning its enzyme-inhibiting effect can persist for approximately four to five days after the last dose is taken. The final time required for the clinical signs of the infection to fully disappear depends on the infection being treated and the body's natural healing process.

Q: Do you need to finish the full course of Fungototal even if you feel better quickly?

A: Official patient guidance consistently states that completing the entire prescribed course of treatment is important. This is advised even if symptoms improve quickly, as stopping treatment prematurely may increase the risk of the infection returning or developing resistance.

How should Fungototal be stored and disposed of?

How to Store and Dispose of Fungototal (Fluconazole)

Official regulatory information details specific storage requirements based on the medicine's form.

Pharmaceutical Form Mandatory Storage Condition
Oral Capsules/Tablets Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Dry Powder for Suspension Store below 30 C (86 F) and protect from moisture.
Reconstituted Suspension Store between 5 C and 30 C and do not freeze.

All forms of the medicine must be stored out of the sight and reach of children. The reconstituted oral suspension has a stability period of 14 days and must be discarded after this time. Unused or expired medication must be disposed of according to local requirements and should not be discarded via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fungototal found in:

A-Z Index: